ABSTRACT
The ongoing pandemic coronavirus disease (COVID-19) is an infection caused by a newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). The treatment of COVID-19 patients represents a continuous challenge, no vaccine or specific antiviral therapy is yet available. International guidelines recommend the medical management based only on the first line physicians' short expertise, off-label approaches being admitted worldwide to limit and to decrease the infection devastating impacts on humans’ health. A marketed drug used for asthma, known generically as montelukast, gives light in the attempt of clinicians during their efforts to combat SARS-CoV2 spreading. Even not yet approved by FDA or EMA for COVID-19 infection indication, many clinicians are raising-up the idea of turning attention and attempts to off-label medical options like montelukast use, considering this drug an alternative or additive therapeutic approach for prevention and treating pulmonary distress.